Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of GRN163L in Patients With Chronic Lymphoproliferative Disease

NCT00124189•Geron Corporation

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the safety and maximum tolerated dose of GRN163L in treating patients with refractory or relapsed chronic lymphoproliferative disease.

Detailed Description

Imetelstat Sodium (GRN163L) is a telomerase template antagonist with in vitro and in vivo activity in a variety of tumor model systems. Telomerase is an enzyme that is active primarily in tumor cells and is crucial for the indefinite growth of tumor cells. Inhibition of telomerase may result in antineoplastic effects. High telomerase levels and short telomere lengths correlate with other markers of poor prognosis in patients with chronic lymphoproliferative disease.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•18 years of age or older
•Male or female
•Chronic lymphoproliferative disease with related biology or similar clinical pattern to B-Cell Leukemia (CLL)including: small lymphocytic lymphoma (SLL), T cell prolymophocytic leukemia (T-PLL), B cell prolymphocytic leukemia (B-PLL), mantle cell lymphoma or other non-Hodgkins lymphoma in leukemic phase (peripheral blood circulating malignant cells present), Waldenstrom's macroglobulinemia
•Must have relapsed from or be refractory to prior therapeutic regimens
•Patients with CLL or SLL must have received at least one prior purine analogue-based chemotherapy regimen (eg, fludarabine, pentostatin or cladribine)
•If previously treated with an anthracycline, anthracenedione, or trastuzumab, must have left ventricular ejection fraction \> 50%
•ECOG performance status 0-2
•Life expectancy 3 months or greater

Exclusion Criteria

•Pregnant or lactating women
•Active 2nd malignancy or history of another malignancy within 2 years, except:treated, non-melanoma skin cancer,treated breast or cervical carcinoma in situ,or resected T1a or b prostate cancer
•Chemotherapeutic agents within 4 weeks prior to study
•High dose CTX with stem cell support within 6 months prior to study
•Signal transduction inhibitors,or monoclonal antibodies within 4 weeks prior to study
•Immunotherapy or biological response modifiers within 4 weeks prior to study
•Systemic hormonal therapy within 4 weeks prior to study
•Anticoagulant therapy, antiplatelet therapy within 2 weeks prior to study
•Radiotherapy within 4 weeks prior to study
•Active autoimmune disorder
+5 more criteria

Locations (8)

Rocky Mountain Cancer Center

Denver, Colorado, United States

Hackensack University Medical Center

Hackensack, New Jersey, United States

Roswell Park Cancer Center

Buffalo, New York, United States

Long Island Jewish Medical Center

New Hyde Park, New York, United States

Weill Medical College of Cornell University

New York, New York, United States

The Ohio State University James Cancer Hospital

Columbus, Ohio, United States

UT Southwestern

Dallas, Texas, United States

University of Texas Health Science Center

San Antonio, Texas, United States

Key Dates

Start Date

July 1, 2005

Primary Completion Date

March 1, 2013

Completion Date

March 1, 2013

Last Updated

December 24, 2015

Enrollment

ESTIMATED participants

Conditions

Chronic Lymphoproliferative Diseases

Interventions

GRN163L

DRUG